Australia - engleză - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - aztreonam, quantity: 75 mg - inhalation, powder for - excipient ingredients: lysine monohydrate; water for injections

Australia - engleză - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aztreonam, quantity: 2.094 g - injection, powder for - excipient ingredients: arginine - aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca, citrobacter species, and serratia marcescens. lower respiratory tract infections, including pneumonia and bronchitis caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, haemophilus influenzae, proteus mirabilis, enterobacter species, and serratia marcescens. septicemia caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, serratia marcescens, and enterobacter species. skin and skin structure infections, including those associated with postoperative wounds, ulcers, and burns, caused by escherichia coli, proteus mirabilis, serratia marcescens, enterobacter species, pseudomonas aeruginosa, klebsiella pneumoniae, and citrobacter species. intra abdominal infections, including peritonitis caused by escherichia coli, klebsiella species including k. pneumoniae, enterobacter species including e. cloacae, pseudomonas aeruginosa, citrobacter species including c. freundii, and serratia species including s. marcescens. gynecologic infections, including endometritis and pelvic cellulitis caused by escherichia coli, klebsiella pneumoniae, enterobacter species including e. cloacae, and proteus mirabilis. aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. aztreonam for injection is effective against most of the commonly encountered gram negative aerobic pathogens seen in general surgery.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aztreonam, quantity: 1.059 g - injection, powder for - excipient ingredients: arginine - aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca, citrobacter species, and serratia marcescens. lower respiratory tract infections, including pneumonia and bronchitis caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, haemophilus influenzae, proteus mirabilis, enterobacter species, and serratia marcescens. septicemia caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, serratia marcescens, and enterobacter species. skin and skin structure infections, including those associated with postoperative wounds, ulcers, and burns, caused by escherichia coli, proteus mirabilis, serratia marcescens, enterobacter species, pseudomonas aeruginosa, klebsiella pneumoniae, and citrobacter species. intra abdominal infections, including peritonitis caused by escherichia coli, klebsiella species including k. pneumoniae, enterobacter species including e. cloacae, pseudomonas aeruginosa, citrobacter species including c. freundii, and serratia species including s. marcescens. gynecologic infections, including endometritis and pelvic cellulitis caused by escherichia coli, klebsiella pneumoniae, enterobacter species including e. cloacae, and proteus mirabilis. aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. aztreonam for injection is effective against most of the commonly encountered gram negative aerobic pathogens seen in general surgery.

Israel - engleză - Ministry of Health

gilead sciences israel ltd - aztreonam - lyophilized powder for nebuliser solution - aztreonam 75 mg/vial - aztreonam - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - engleză - Ministry of Health

gilead sciences israel ltd - aztreonam - lyophilized powder for nebuliser solution - aztreonam 75 mg/vial - aztreonam - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lysine - cystic fibrosis; respiratory tract infections - antibacterials for systemic use, - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - aztreonam 1 g; aztreonam 1 g - powder for injection - 1 g - active: aztreonam 1 g excipient: arginine active: aztreonam 1 g excipient: arginine - for the treatment of infections caused by susceptible gram-negative microorganisms. it has been used successfully to treat: urinary tract infections (including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to the pathogens resistant to the aminoglycosides, cephalosporins or penicillins); lower respiratory tract infections (including pneumonia and bronchitis); bacteraemia/septicemia; bone and joint infections; skin and skin-structure infections (including those associated with postoperative wounds, ulcers and burns); intra-abdominal infections (including peritonitis); gynaecologic infections (including pelvic inflammatory disease, endometritis, and pelvic cellulitis); gonorrhoea (acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of n.gonorrhoeae). before instituting treatment with azactam, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. treatment with azactam may be started empirically before results of the susceptibility testing are available. concurrent therapy: in seriously ill patients, additional antibiotic therapy should be initiated concurrently with azactam to provide broad-spectrum coverage before identification and susceptibility testing results of the causative organism(s) are known. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an amino-glycoside because of synergistic action. these agents are also synergistic in vitro against many strains of enterobacteriaceae, and other gram-negative aerobic baccilli. however, this enhanced activity is not predictable.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - aztreonam - powder for solution for injection/infusion - 1 gram(s) - monobactams; aztreonam

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - aztreonam - powder for solution for injection/infusion - 2 gram(s) - monobactams; aztreonam

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bristol-myers squibb belgium sa-nv - aztreonam 1 g - powder for solution for injection - 1 g - aztreonam 1000 mg - aztreonam